98%
921
2 minutes
20
Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (CRPC), treatment is inevitably hampered by the development of drug resistance. Thus, new drugs are urgently needed. We investigated the efficacy, toxicity, and mechanism of action of the marine triterpene glycoside cucumarioside A-2 (CA-2) using an in vitro CRPC model. CA-2 induced a G/M-phase cell cycle arrest in human prostate cancer PC-3 cells and caspase-dependent apoptosis executed via an intrinsic pathway. Additionally, the drug inhibited the formation and growth of CRPC cell colonies at low micromolar concentrations. A global proteome analysis performed using the 2D-PAGE technique, followed by MALDI-MS and bioinformatical evaluation, revealed alterations in the proteins involved in cellular processes such as metastatic potential, invasion, and apoptosis. Among others, the regulation of keratin 81, CrkII, IL-1β, and cathepsin B could be identified by our proteomics approach. The effects were validated on the protein level by a 2D Western blotting analysis. Our results demonstrate the promising anticancer activity of CA-2 in a prostate cancer model and provide insights on the underlying mode of action.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10817243 | PMC |
http://dx.doi.org/10.3390/md22010020 | DOI Listing |
Ann Surg Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Objective: To examine differences in cancer-specific mortality (CSM) in nonmetastatic upper tract urothelial carcinoma (UTUC) patients with vs. without secondary bladder cancer (BCa) after radical nephroureterectomy (RNU).
Methods: Within the Surveillance, Epidemiology, and End Results database (SEER 2000-2021), T1-T4N0M0 UTUC patients treated with RNU and diagnosed with secondary BCa were identified.
Eur Urol Oncol
September 2025
The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Background And Objective: The effect of family history (FH) on prostate cancer active surveillance outcomes is unknown. Our objective is to evaluate FH of prostate, breast, ovarian, and/or pancreatic cancer in a large prospective active surveillance cohort.
Methods: Patients with recorded FH data (N = 1421) were selected.
Int J Radiat Oncol Biol Phys
October 2025
Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Int J Radiat Oncol Biol Phys
October 2025
Division of Radiation oncology, Department of Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Electronic address: